<DOC>
	<DOCNO>NCT00005785</DOCNO>
	<brief_summary>This study investigate safety effectiveness new stem cell transplant procedure treat acute chronic leukemia , multiple myeloma , myelodysplastic syndrome , Hodgkin 's non-Hodgkin 's lymphoma HIV-infected patient . HIV-infected patient usually offer bone marrow transplant treatment increase risk die intense chemotherapy radiation therapy use procedure . This study use modified procedure , transplant stem cell instead bone marrow , design less dangerous patient . Patients also undergo procedure call gene transfer try halt progression HIV infection . The procedure study differs standard bone marrow transplantation three way : Stem cell transplant instead bone marrow . ( Stem cell , produce bone marrow , mature different blood components-white red cell platelet . ) The stem cell donor give drug release cell bone marrow blood stream . The cell collect donor apheresis , procedure whole blood drawn , stem cell separate remove , rest blood return donor . ) ; The procedure use low dos chemotherapy conventional method , use radiation therapy ; A laboratory-manufactured gene design obstruct HIV reproduction insert stem cell , render future cell develop resistance virus . Prospective patient test match HIV-negative donor ( family member ) undergo medical history , physical examination several test ( e.g. , breathe test , X-rays , etc . ) determine eligibility study . Study participant undergo apheresis collect white blood cell call lymphocyte . Stem cell collect donor . Half donate cell HIV-resistant gene insert ; half `` control '' gene insert . Additional stem cell collected second day manipulate . All donor cell frozen transplantation . Patients give drug ( cyclophosphamide , fludarabine cyclosporin ) prevent donate cell reject prevent damaging patient 's organ . The thawed stem cell infuse vein . After 30 , 60 100 day , bone marrow cell circulate lymphocyte check see many donor cell origin . If less 100 percent donor origin , lymphocytes transfuse . Patients physical examination blood test twice week 2 3 month follow periodically least 5 year .</brief_summary>
	<brief_title>Stem Cell ( Modified Bone Marrow ) Transplantation HIV-Infected Patients With Blood Cancer</brief_title>
	<detailed_description>Adult patient myelodysplasia , leukemia , non-Hodgkin 's lymphoma cure allogeneic bone marrow transplantation ( BMT ) . This curative effect ascribe intense chemoradiotherapy use condition recipient transplantation . The assumption curative effect allogeneic transplantation rest ability deliver high dos chemoradiotherapy lead restriction allogeneic transplantation recipient patient whose overall status would permit use intense conditioning . As result , HIV positivity generally appear exclusion criterion allogeneic transplantation hematologic malignancy . Additionally , early study allogeneic BMT HIV patient suggest benefit control progression AIDS . Several vitro study demonstrate existence donor derive CD4 CD8 positive lymphocyte specific reactivity recipient leukemia provide potent graft versus leukemia ( GVL ) effect , GVL effect area intense interest NIH elsewhere . In fact , early attempt decrease treatment related mortality chronic myelogenous leukemia ( CML ) patient undergo allogeneic BMT T-cell depletion graft result unacceptably high rate relapse suggest alloreactivity donor graft account significant portion cure rate disease . This GVL effect dramatically demonstrate among relapsed allogeneic bone marrow transplant recipient transplant CML simple infusion donor lymphocytes induce complete durable remission . Non-myeloablative allogeneic peripheral blood stem cell transplant currently investigate engraftment efficacy toxicity number transplant center . Preliminary data include experience 13 patient undergoing type procedure show high rate complete donor engraftment , low toxicity , preservation GVL effect . Two recent publish study investigate non-myeloablative allo-transplantation standard risk patient reveal extremely low rate transplant relate complication mortality . The decreased risk transplant related complication associate non-myeloablative transplant expand eligibility transplant candidate may allow successful application patient infected HIV . In study , assess safety efficacy nonmyeloablative transplantation patient HIV infection . Moreover , introduction HIV resistance vector portion allogeneic graft provide unique opportunity test vivo efficacy introduce resistance HIV self renew stem cell . The end point study engraftment , degree donor-host chimerism , incidence acute chronic GVHD , transplant relate morbidity mortality , disease free survival , well overall survival , overall level persistence progeny gene modify cell .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<criteria>PATIENTS : Patients hematologic malignancy curable allogeneic BMT currently consider transplant HIV positivity . Chronic myelogenous leukemia ( CML ) : chronic phase . Acute lymphoblastic leukemia ( ALL ) , patient complete partial remission . Acute myelogenous leukemia ( AML ) : AML first complete partial remission . ( Exceptions : AML good risk karyotype : AML M3t , AML M4Eo , AML t. All AML second subsequent complete remission . ) Myelodysplastic syndrome : refractory anemia ( fail ATG and/or CSA ) early transformation acute leukemia . Chronic myelomonocytic leukemia myeloproliferative disease . Chronic lymphocytic leukemia ( CLL ) prolymphocytic leukemia , complete partial remission , Mantle cell lymphoma , relapse Hodgkin 's nonHodgkin 's lymphoma . Multiple myeloma remission follow chemotherapy . No major organ dysfunction preclude transplantation . DLCO great 40 percent predict . Left ventricular ejection fraction great 30 percent . ECOG performance status 0 2 . DONOR : HLA identical sibling donor . Fit receive GCSF give peripheral blood stem cell ( normal blood count , normotensive , history stroke , history severe heart disease ) . Informed consent give . DONOR AND PATIENT : Must pregnant lactating . Must 18 80 year age . Must ECOG performance status 3 . Must psychiatric disorder mental deficiency patient donor sufficiently severe make compliance BMT treatment unlikely , make informed consent impossible . Must major anticipated illness organ failure incompatible survival BMT determine NIH physician ( include encephalopathy , cardiomyopathy , hepatitis . ) Must DLCO le 40 percent predict . Must glomerular filtration rate le 40 . Must serum bilirubin great 4 mg/dl , transaminases great 4x upper limit normal . Donor must HIV negative . Donors positive HBV , HCV HTLV use discretion investigator . Must malignant disease liable relapse progress within 5 year . Donor must fit receive GCSF undergo apheresis . ( Uncontrolled hypertension , history congestive heart failure unstable angina , thrombocytopenia ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2001</verification_date>
	<keyword>Peripheral Blood Stem Cells</keyword>
	<keyword>Engraftment</keyword>
	<keyword>Graft v . Host Disease</keyword>
	<keyword>Graft-Versus-Leukemia</keyword>
	<keyword>Donor Apheresis</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>HIV</keyword>
	<keyword>AIDS</keyword>
	<keyword>Gene Therapy</keyword>
	<keyword>Chronic Myelogenous Leukemia</keyword>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
</DOC>